Kenya confirmed its third case of Bundibugyo Ebola on Friday — a 65-year-old woman who is a close relative of the first patient, who died October 5 after flying from Uganda to Nairobi. She had been in quarantine since October 6, developed symptoms, and tested positive. Kenya's Health Ministry says 127 of 130 traced contacts are in quarantine and insists the risk of community transmission remains low. The epidemiological chain is clear: a Kenyan man fell ill in the DRC, traveled overland to Uganda, flew to Nairobi, was driven to hospital by a relative, and died within two days. Two family contacts have since tested positive. The containment story depends entirely on contact tracing holding — 127 of 130 is a good ratio, but three untraced contacts in a dense urban environment is a nonzero problem. Behind the Kenyan cases sits the DRC's epidemic, the second-largest Ebola outbreak on record: more than 9,000 cases and over 4,300 deaths since May. It has now spread to an eighth Congolese province, North Ubangi, which borders the Central African Republic. The geographic expansion is the structural signal — containment lines are not holding in the DRC, and every new province is a new vector for cross-border transmission. The most corrosive revelation is financial. The Africa CDC says international donors disbursed roughly $962 million to organizations implementing the Ebola response — not to the Congolese government. Of that, implementing organizations reported receiving only $228 million. Of that $228 million, $127 million has been spent and about $100 million remains. That leaves more than $700 million unaccounted for. Africa CDC Director General Jean Kaseya stopped short of calling it embezzlement but the arithmetic is stark. Congolese Health Minister Samuel Roger Kamba responded with a direct threat: aid organizations must disclose funding sources or face expulsion from the DRC and blacklisting across Africa. Whether this is genuine transparency enforcement or political leverage depends on follow-through, but the underlying problem is structural. Response funding flowed to intermediary organizations rather than through government systems, creating an accountability vacuum between disbursement and delivery. The critical technical gap compounds every other failure. The Bundibugyo strain has no licensed vaccine. Research is underway and some candidates are in early human trials, but there is no deployable tool equivalent to the rVSV-ZEBOV vaccine that helped contain the 2018-2020 Kivu Ebola outbreak. Every containment effort is therefore manual — contact tracing, isolation, supportive care — with no pharmacological backstop. The pattern is one the global health system has seen before: a containment-dependent response in a resource-constrained environment, funded through opaque intermediary channels, racing an expanding geographic footprint, with no vaccine safety net. Kenya's three cases are manageable in isolation. The DRC's 9,000-case epidemic spreading to its eighth province while $700 million in response funds vanish into organizational black boxes is not.
